Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.83 |
| ▸ | FLT1 | P17948 | 17/20 | 0.83 |
| ▸ | FLT4 | P35916 | 17/20 | 0.83 |
| ▸ | FGFR1 | P11362 | 15/20 | 0.73 |
| ▸ | FGFR2 | P21802 | 12/20 | 0.73 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.73 |
| ▸ | FGFR3 | P22607 | 12/20 | 0.73 |
| ▸ | LCK | P06239 | 4/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597080 | 0.91 | KDR (1.00) | KDRFLT1FLT4FGFR1FGFR2 | |
| SCHEMBL5606960 | 0.89 | KDR (0.80) | KDRFLT1FLT4FGFR1FGFR2 | |
| SCHEMBL5607151 | 0.87 | KDR (0.87) | KDRFLT1FLT4FGFR1FGFR2 | |
| SCHEMBL1227532 | 0.87 | KDR (0.81) | KDRFLT1FLT4FGFR1FGFR2 | |
| SCHEMBL5606057 | 0.86 | KDR (0.83) | KDRFLT1FLT4FGFR1FGFR2 | |
| SCHEMBL5605877 | 0.85 | KDR (1.00) | KDRFLT1FLT4FGFR1FGFR2 | |
| SCHEMBL6446207 | 0.85 | KDR (0.81) | KDRFLT1FLT4FGFR1FGFR2 | |
| SCHEMBL6450637 | 0.85 | KDR (0.92) | KDRFLT1FLT4FGFR1FGFR2 | |
| SCHEMBL6448093 | 0.84 | KDR (1.00) | KDRFLT1FLT4FGFR1FGFR2 | |
| SCHEMBL6447437 | 0.84 | KDR (0.88) | KDRFLT1FLT4FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | BHIDE RAJEEV S | 2005-10-20 | — | — | US | claimed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KDR 7/4885FLT1 2/4885FLT4 5/4885 |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KDR 7/4885FLT1 2/4885FLT4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.